Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

New coronary IVL tech from Boston Scientific impresses in first-in-human study

Summary by cardiovascularbusiness.com
The company's Seismiq platform has already gained FDA approval for treating PAD. This new analysis highlights its potential to treat calcified coronary lesions during PCI procedures.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

cardiovascularbusiness.comcardiovascularbusiness.com

New coronary IVL tech from Boston Scientific impresses in first-in-human study

The company's Seismiq platform has already gained FDA approval for treating PAD. This new analysis highlights its potential to treat calcified coronary lesions during PCI procedures.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

cardiovascularbusiness.com broke the news on Monday, May 11, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Marlborough, Massachusetts icon

Marlborough, Massachusetts

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal